James S. Shannon Rejoins MannKind's Board of Directors
May 21 2015 - 10:30AM
MannKind Corporation (Nasdaq:MNKD) today announced
that James S. Shannon, MD, MRCP (UK) has been elected to the
company's Board of Directors after previously serving as a director
from February 2010 until April 2012. The addition of Dr. Shannon
brings the total number of MannKind Board members to eight.
From May 2012 until his retirement in April 2015, Dr. Shannon
was the Chief Medical Officer of GlaxoSmithKline. He formerly held
the position of Global Head of Pharma Development at Novartis AG,
based in Basel, Switzerland from 2005 until 2008. After joining
Sandoz in 1994 as Head of Drug Regulatory Affairs, Dr. Shannon led
of the Integration Office for R&D overseeing the creation of
the Novartis R&D groups from those of Ciba-Geigy Ltd and
Sandoz. Following the merger he was appointed Head of the
Cardiovascular Strategic Team and subsequently became Global Head
of Project Management before being appointed Global Head of
Clinical Development and Medical Affairs in 1999, a position that
he held until 2005 when he was appointed to Head Pharma
Development. Between 2008 and joining GSK, Dr. Shannon served on
the boards of a number of companies, including Biotie, Circassia,
Crucell, Endocyte and MannKind. He also sat on the board of Cerimon
Pharmaceuticals where he held the position of interim Chief
Executive Officer and President from January 2009 until April 2010.
He first entered the pharmaceutical industry in 1987 joining
Sterling Winthrop Inc., working initially in Europe and
subsequently in the USA, where he held positions of increasing
responsibility in the management of research and development
ultimately serving as Senior Vice-President, Clinical Development.
Dr. Shannon is trained in Medicine and Cardiology. He received his
undergraduate and postgraduate degrees at Queen's University of
Belfast and is a Member of the Royal College of Physicians
(UK).
"We are very pleased to welcome James back to the board of
directors," stated Alfred Mann, Executive Chairman of MannKind
Corporation. "His experience as a recognized pharmaceutical
industry leader is invaluable to us as we accelerate the
commercialization of Afrezza® and build a pipeline of additional
product opportunities that utilize our proprietary
technologies."
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) focuses on the discovery and
development of therapeutic products for patients with diseases such
as diabetes. MannKind maintains a website at
http://www.mannkindcorp.com to which MannKind regularly posts
copies of its press releases as well as additional information
about MannKind. Interested persons can subscribe on the MannKind
website to e-mail alerts that are sent automatically when MannKind
issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the
website.
CONTACT: Company Contact:
Matthew J. Pfeffer
Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024